Nurse Practitioner Program year 2023 Reported 2021–2023 Source: CMS Open Payments, 2026 publication

Lisa Lindsay

Nurse Practitioner, Gerontology Flint, MI Nurse Practitioner

NPI 1962507947 CMS profile 11042945

2 Hurley Plz, 211, Flint, MI 48503

Open in the dashboard

General payments

$2,561

141 records reported · program years 2021–2023

Research payments

$0

Paid to them · None reported · program years 2021–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Lisa Lindsay of Flint, MI is reported in the CMS Open Payments database as having received $2,561 across 141 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 86th percentile of Nurse Practitioner, Gerontology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $80 5
2022 General $972 53
2021 General $1,509 83

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Lisa Lindsay
  • Nurse Practitioner, Gerontology median
  • Middle half of Nurse Practitioner, Gerontology
  • National median

In program year 2025, general payments to Lisa Lindsay were reported at $0. Among 4,139 Nurse Practitioner, Gerontology profiles paid that year, the median was $179 and the middle half received between $55 and $547.

Show as a table
Year Lisa Lindsay Nurse Practitioner, Gerontology median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $1,509 $133 $44–$396 $132
2022 $972 $142 $48–$452 $149
2023 $80 $158 $53–$482 $160
2024 $0 $171 $55–$533 $164
2025 $0 $179 $55–$547 $169

Breakdown

Who paid General payments · program years 2021–2023
  1. ITI, Inc. $242 9 payments
  2. UCB, Inc. $213 9 payments
  3. AbbVie, Inc. $195 13 payments
  4. Alkermes, Inc. $185 10 payments
  5. Sunovion Pharmaceuticals Inc. $179 11 payments
  6. Neurelis, Inc. $128 8 payments
  7. Amgen Inc. $119 6 payments
  8. Astellas Pharma US Inc $119 8 payments
  9. Salix Pharmaceuticals, a division of Bausch Health US, LLC $112 7 payments
  10. Janssen Pharmaceuticals, Inc $104 6 payments
  11. Other $965 54 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2023
  1. Food and Beverage $2,468 140 payments
  2. Education $94 1 payment
Products named General payments · program years 2021–2023
  1. CAPLYTA $242 9 payments
  2. Briviact $196 8 payments
  3. GEMTESA $192 12 payments
  4. ARISTADA INITIO $185 10 payments
  5. ARISTADA Cns $185 10 payments
  6. ARISTADA Cns $185 10 payments
  7. LYBALVI Cns $140 8 payments
  8. LYBALVI Cns $140 8 payments
  9. VALTOCO $128 8 payments
  10. AIMOVIG $119 6 payments
  11. Other $2,087 120 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 257 drugs

Part D claims

25,261

Median for Nurse Practitioner: 389

Drug cost

$1,333,295

Median for Nurse Practitioner: $21,885

Branded share of claims

16%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 236 $148,285
Trulicity Dulaglutide Brand 98 $99,049
Briviact Brivaracetam Brand 54 $78,430
Otezla Apremilast Brand 12 $62,727
Januvia Sitagliptin Phosphate Brand 85 $48,628
Xarelto Rivaroxaban Brand 64 $44,235
Myrbetriq Mirabegron Brand 85 $40,178
Breo Ellipta Fluticasone/Vilanterol Brand 96 $39,614
Linzess Linaclotide Brand 56 $30,598
Nuedexta Dextromethorphan Hbr/Quinidine Brand 31 $28,477

The 10 drugs with the highest cost, of 257 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 9 billing codes

Paid by Medicare

$22,556

Medicare's payments for the services billed

Medicare patients

296

Average age 57

Services billed

822

115 women, 181 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Diabetes 75%
High blood pressure 64%
Arthritis 41%
COPD 21%
Depression 21%
Chronic kidney disease 18%
Alzheimer's or dementia 12%
Ischemic heart disease 10%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

141 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Gerontology in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record